OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?
Sheheryar Kabraji, Jing Ni, Nancy U. Lin, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 8, pp. 1795-1804
Open Access | Times Cited: 79
Sheheryar Kabraji, Jing Ni, Nancy U. Lin, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 8, pp. 1795-1804
Open Access | Times Cited: 79
Showing 1-25 of 79 citing articles:
Breast Cancer Treatment
Adrienne G. Waks, Eric P. Winer
JAMA (2019) Vol. 321, Iss. 3, pp. 288-288
Closed Access | Times Cited: 3667
Adrienne G. Waks, Eric P. Winer
JAMA (2019) Vol. 321, Iss. 3, pp. 288-288
Closed Access | Times Cited: 3667
The blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Costas D. Arvanitis, Gino B. Ferraro, Rakesh K. Jain
Nature reviews. Cancer (2019) Vol. 20, Iss. 1, pp. 26-41
Open Access | Times Cited: 1270
Costas D. Arvanitis, Gino B. Ferraro, Rakesh K. Jain
Nature reviews. Cancer (2019) Vol. 20, Iss. 1, pp. 26-41
Open Access | Times Cited: 1270
Brain metastases
Achal S. Achrol, Robert C. Rennert, Carey K. Anders, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 789
Achal S. Achrol, Robert C. Rennert, Carey K. Anders, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 789
Fatty acid synthesis is required for breast cancer brain metastasis
Gino B. Ferraro, Ahmed Ali, Alba Luengo, et al.
Nature Cancer (2021) Vol. 2, Iss. 4, pp. 414-428
Open Access | Times Cited: 244
Gino B. Ferraro, Ahmed Ali, Alba Luengo, et al.
Nature Cancer (2021) Vol. 2, Iss. 4, pp. 414-428
Open Access | Times Cited: 244
Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption
Costas D. Arvanitis, Vasileios Askoxylakis, Yutong Guo, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 37
Open Access | Times Cited: 202
Costas D. Arvanitis, Vasileios Askoxylakis, Yutong Guo, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 37
Open Access | Times Cited: 202
Treatment strategies for breast cancer brain metastases
Caroline Bailleux, Lauriane Eberst, Thomas Bachelot
British Journal of Cancer (2020) Vol. 124, Iss. 1, pp. 142-155
Open Access | Times Cited: 183
Caroline Bailleux, Lauriane Eberst, Thomas Bachelot
British Journal of Cancer (2020) Vol. 124, Iss. 1, pp. 142-155
Open Access | Times Cited: 183
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy
Bolong Tao, Ruoxin Du, Xiangmei Zhang, et al.
Journal of Controlled Release (2023) Vol. 363, pp. 692-706
Closed Access | Times Cited: 43
Bolong Tao, Ruoxin Du, Xiangmei Zhang, et al.
Journal of Controlled Release (2023) Vol. 363, pp. 692-706
Closed Access | Times Cited: 43
Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis
Aadya Nagpal, Richard P. Redvers, Xiawei Ling, et al.
Breast Cancer Research (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 122
Aadya Nagpal, Richard P. Redvers, Xiawei Ling, et al.
Breast Cancer Research (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 122
Understanding the biology of HER3 receptor as a therapeutic target in human cancer
Hui Lyu, Amy Han, Erik Polsdofer, et al.
Acta Pharmaceutica Sinica B (2018) Vol. 8, Iss. 4, pp. 503-510
Open Access | Times Cited: 104
Hui Lyu, Amy Han, Erik Polsdofer, et al.
Acta Pharmaceutica Sinica B (2018) Vol. 8, Iss. 4, pp. 503-510
Open Access | Times Cited: 104
HER2-positive advanced breast cancer treatment in 2020
Marcelle Goldner Cesca, Lucas Vian, Sofia Cristóvão‐Ferreira, et al.
Cancer Treatment Reviews (2020) Vol. 88, pp. 102033-102033
Closed Access | Times Cited: 102
Marcelle Goldner Cesca, Lucas Vian, Sofia Cristóvão‐Ferreira, et al.
Cancer Treatment Reviews (2020) Vol. 88, pp. 102033-102033
Closed Access | Times Cited: 102
Alexandra S. Zimmer, Amanda E.D. Van Swearingen, Carey K. Anders
Cancer Reports (2020) Vol. 5, Iss. 4
Open Access | Times Cited: 90
Molecular Mechanisms Underlying Autophagy-Mediated Treatment Resistance in Cancer
Cally J. Ho, Sharon M. Gorski
Cancers (2019) Vol. 11, Iss. 11, pp. 1775-1775
Open Access | Times Cited: 82
Cally J. Ho, Sharon M. Gorski
Cancers (2019) Vol. 11, Iss. 11, pp. 1775-1775
Open Access | Times Cited: 82
HIF1A signaling selectively supports proliferation of breast cancer in the brain
Richard Y. Ebright, Marcus Zachariah, Douglas S. Micalizzi, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 80
Richard Y. Ebright, Marcus Zachariah, Douglas S. Micalizzi, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 80
Targeting brain metastases in breast cancer
Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello, et al.
Cancer Treatment Reviews (2021) Vol. 103, pp. 102324-102324
Closed Access | Times Cited: 79
Chiara Corti, Gabriele Antonarelli, Carmen Criscitiello, et al.
Cancer Treatment Reviews (2021) Vol. 103, pp. 102324-102324
Closed Access | Times Cited: 79
Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
Chikashi Watase, Sho Shiino, Tatsunori Shimoi, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1078-1078
Open Access | Times Cited: 70
Chikashi Watase, Sho Shiino, Tatsunori Shimoi, et al.
Cancers (2021) Vol. 13, Iss. 5, pp. 1078-1078
Open Access | Times Cited: 70
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Sheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 174-182
Open Access | Times Cited: 63
Sheheryar Kabraji, Jing Ni, Sarah Sammons, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 174-182
Open Access | Times Cited: 63
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness
Pravat Kumar Parida, Mauricio Marquez-Palencia, Vidhya R. Nair, et al.
Cell Metabolism (2022) Vol. 34, Iss. 1, pp. 90-105.e7
Open Access | Times Cited: 62
Pravat Kumar Parida, Mauricio Marquez-Palencia, Vidhya R. Nair, et al.
Cell Metabolism (2022) Vol. 34, Iss. 1, pp. 90-105.e7
Open Access | Times Cited: 62
Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases
Pravat Kumar Parida, Mauricio Marquez-Palencia, Suvranil Ghosh, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 893-907
Closed Access | Times Cited: 40
Pravat Kumar Parida, Mauricio Marquez-Palencia, Suvranil Ghosh, et al.
Nature Cancer (2023) Vol. 4, Iss. 6, pp. 893-907
Closed Access | Times Cited: 40
The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
Franziska M. Ippen, Christopher Alvarez‐Breckenridge, Benjamin M. Kuter, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 11, pp. 3374-3383
Open Access | Times Cited: 67
Franziska M. Ippen, Christopher Alvarez‐Breckenridge, Benjamin M. Kuter, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 11, pp. 3374-3383
Open Access | Times Cited: 67
Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer
Jimena G. Dancy, Aniket S. Wadajkar, Nina P. Connolly, et al.
Science Advances (2020) Vol. 6, Iss. 3
Open Access | Times Cited: 63
Jimena G. Dancy, Aniket S. Wadajkar, Nina P. Connolly, et al.
Science Advances (2020) Vol. 6, Iss. 3
Open Access | Times Cited: 63
Development of Effective Therapeutics Targeting HER3 for Cancer Treatment
Xiaolong Liu, Shuang Liu, Hui Lyu, et al.
Biological Procedures Online (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 62
Xiaolong Liu, Shuang Liu, Hui Lyu, et al.
Biological Procedures Online (2019) Vol. 21, Iss. 1
Open Access | Times Cited: 62
PMPC Modified PAMAM Dendrimer Enhances Brain Tumor‐Targeted Drug Delivery
Jiamin Ban, Sidi Li, Qi Zhan, et al.
Macromolecular Bioscience (2021) Vol. 21, Iss. 4
Closed Access | Times Cited: 44
Jiamin Ban, Sidi Li, Qi Zhan, et al.
Macromolecular Bioscience (2021) Vol. 21, Iss. 4
Closed Access | Times Cited: 44
RET signaling in breast cancer therapeutic resistance and metastasis
Geoffrey Pecar, Simeng Liu, Jagmohan Hooda, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 18
Geoffrey Pecar, Simeng Liu, Jagmohan Hooda, et al.
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 18
Suppressing Wnt signaling of the blood‒tumor barrier to intensify drug delivery and inhibit lipogenesis of brain metastases
Yang Tong, Pei An, Puxian Tang, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2716-2731
Open Access | Times Cited: 8
Yang Tong, Pei An, Puxian Tang, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2716-2731
Open Access | Times Cited: 8
Cancer–stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies
Marie-Anne Goyette, Laura E. Stevens, Carolyn R. DePinho, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 20
Open Access | Times Cited: 7
Marie-Anne Goyette, Laura E. Stevens, Carolyn R. DePinho, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 20
Open Access | Times Cited: 7
